Evidence map›Paper›PMID 41922519›Full record

ArticleNature cell biology2026

Programmable macromolecule delivery via engineered trogocytosis.

Xinyi Chen, Yinglin Situ, Yuexuan Yang, Luna Lyu, Mengting Han, Lorenzo Magni, Maylin L Fu, Boxiong Deng, Sui Wang, Lei S Qi

Abstract read
In one paragraph

Article in Nature cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Programming T cells for intercellular genome editing.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Xinyi ChenDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3365-4284
Yinglin SituDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0009-0007-3810-2626
Yuexuan YangDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0009-0005-6482-5997
Luna LyuInstitute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA.
Mengting HanDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Lorenzo MagniDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Maylin L FuDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3749-5003
Boxiong DengDepartment of Ophthalmology, Mary M. and Sash A. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, CA, USA.
Sui WangDepartment of Ophthalmology, Mary M. and Sash A. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1563-9117
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA, USA. slqi@stanford.edu.ORCID http://orcid.org/0000-0002-3965-3223

Funding

Manipulating and Interrogating Spatial TranscriptomicsDP1NS137219 · NINDS · STANFORD UNIVERSITY · PI Lei Stanley Qi · 2023 to 2026
$4.3M
High resolution dissection of oncogene enhancer networks via CRISPR screening and live-cell imaging.R01CA266470 · NCI · STANFORD UNIVERSITY · PI Lei Stanley Qi · 2022 to 2026
$1.9M
Probing relationships between DNA methylation and cellular senescence with high-throughput CRISPR-based epigenetic editingR21AG077193 · NIA · STANFORD UNIVERSITY · PI QI, LEI STANLEY · 2023 to 2024
$425k
Unveil the Functional Role of RNA Spatial Localization in Neuronal Function and Neurodegeneration by Developing Novel CRISPR-TO ToolsF31NS147860 · NINDS · STANFORD UNIVERSITY · PI Maylin Fu · 2025 to 2026
$94k
DH | NIHR | Efficacy and Mechanism Evaluation Programme (NIHR Efficacy and Mechanism Evaluation Programme) R01CA266470National Science Foundation (NSF) 2046650NCI NIH HHS R01 CA266470NIA NIH HHS R21 AG077193NINDS NIH HHS DP1 NS137219NINDS NIH HHS F31 NS147860U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA266470; R21AG077193; DP1NS137219
6 · The paper itself

Abstract

Trogocytosis, the transfer of plasma membrane fragments during cell-cell contact, offers potential for macromolecular delivery but is limited by the uncertain fate of trogocytosed molecules, restriction to membrane cargo and unclear generalizability. Here we demonstrate that donor cells engineered with designed receptors specific to surface ligands can transfer proteins to recipient cells through direct contact. We identified key engineering principles for enhancing transfer and ensuring cargo functionalization, including receptor design, pH-responsive membrane fusion, inducible cargo localization and release, and subcellular translocation. The method is broadly applicable across diverse cell types and operates through a dynamin- and endosome acidification-dependent pathway. Exploiting these findings, we developed TRANSFER, a versatile delivery system with programmable cell type specificity and tunability. TRANSFER can sense multiple ligand inputs, deliver large therapeutic protein cargos and mediate genome editing. The study establishes trogocytosis as a programmable, versatile framework for cell-based macromolecular delivery.

Indexed as

Cell MembraneMacromolecular SubstancesAnimalsDynaminsEndosomesHumansHydrogen-Ion ConcentrationLigandsMembrane FusionProtein TransportDynaminsLigandsMacromolecular Substances

Identifiers

PMID41922519
PMCPMC13375234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.